These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32842835)

  • 21. Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; Brusse E; Jacobs BC; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Fokkink WR; Nieboer D; Lingsma HF; Merkies ISJ; van Doorn PA
    Eur J Neurol; 2021 Jan; 28(1):286-296. PubMed ID: 32876962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of IVIg in autoimmune neuropathies: the latest evidence.
    Hughes R
    J Neurol; 2008 Jul; 255 Suppl 3():7-11. PubMed ID: 18685920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
    Gorson KC; Natarajan N; Ropper AH; Weinstein R
    Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
    Hansen PN; Mohammed AA; Markvardsen LK; Andersen H; Tankisi H; Sindrup SH; Krøigård T
    J Peripher Nerv Syst; 2023 Sep; 28(3):425-435. PubMed ID: 37212187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CIDP prognosis in patients with IVIG treatment-related fluctuations.
    Cook M; Pasnoor M; Ajroud-Driss S; Brannagan TH; Dimachkie MM; Allen JA
    Muscle Nerve; 2023 Jan; 67(1):69-73. PubMed ID: 36330716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).
    Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
    J Peripher Nerv Syst; 2018 Mar; 23(1):5-10. PubMed ID: 29119642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.
    Marsh EA; Hirst CL; Llewelyn JG; Cossburn MD; Reilly MM; Krishnan A; Doran M; Ryan AM; Coles AJ; Jones JL; Robertson NP
    J Neurol; 2010 Jun; 257(6):913-9. PubMed ID: 20049473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
    Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
    Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.
    Adrichem ME; Eftimov F; van Schaik IN
    J Peripher Nerv Syst; 2016 Sep; 21(3):121-7. PubMed ID: 27241239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; van Doorn PA; Bengrine T; van Rijs W; Baas F; Nagelkerke SQ; Kuijpers TW; Fokkink WR; Bunschoten C; Broers MC; Willemsen SP; Jacobs BC; Huizinga R
    Eur J Neurol; 2021 May; 28(5):1677-1683. PubMed ID: 33460483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
    Broyles R; Rodden L; Riley P; Berger M
    Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
    Terhoeven P; Seybold J; Utz KS; Nickel FT; Lee DH; Linker RA
    J Neurol Sci; 2020 Dec; 419():117169. PubMed ID: 33035867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in systemic lupus erythematosus (SLE) with oral cyclophosphamide.
    Jasmin R; Sockalingam S; Shahrizaila N; Cheah TE; Zain AA; Goh KJ
    Lupus; 2012 Sep; 21(10):1119-23. PubMed ID: 22433918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current treatments of chronic immune-mediated demyelinating polyneuropathies.
    Brannagan TH
    Muscle Nerve; 2009 May; 39(5):563-78. PubMed ID: 19301378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
    Bril V; Hadden RDM; Brannagan TH; Bar M; Chroni E; Rejdak K; Rivero A; Andersen H; Latov N; Levine T; Pasnoor M; Sacconi S; Souayah N; Anderson-Smits C; Duff K; Greco E; Hasan S; Li Z; Yel L; Ay H
    J Peripher Nerv Syst; 2023 Sep; 28(3):436-449. PubMed ID: 37314318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of somatosensory evoked potentials in the assessment of response to IVIG in a long-lasting case of chronic immune sensory polyradiculopathy.
    Clerici AM; Nobile-Orazio E; Mauri M; Squellati FS; Bono GG
    BMC Neurol; 2017 Jul; 17(1):127. PubMed ID: 28668085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.